Theilgaard-Mönch Group

​​The major focus of the Theilgaard-Mönch group is to compare cancer cells to their closest normal cellular counterpart using a variety of omics technologies in order to improve prognostication as well as identify novel targets for treatment of patients with acute myeloid leukaemia (AML).

​​​​​​​​​​​​​​​​​​​​​

The Theilgaard-Mönch Group is part of the Section for stem and cancer stem cell biology.

Research focus 

Our research is focused on three main issues:

  • Mapping of clonal hierarchies in patients with acute myeloid leukaemia (AML)​
  • Identification and validation of therapeutic targeting of oncogenic signaling pathways in patients with AML
  • Application of genomcis, transcriptomics and proteomics technologies to improve prediction of therapy response in patients with AML

Key results

Development of bioinformatics platforms and pre-clinical models for identification and therapeutic targeting of abbarant oncogenic signaling in AML patients.

Group leader: Kim Theilgaard-Mönch​

Kim Theilgaard-Mönch obtained his MD degree from the University of Heidelberg and his DMSc degree from the University of Copenhagen. Since 2013 he holds a Novo Nordisk Clinical Research Fellowship and works as group leader/associate professor and clinician.

Research grants

Our work is funded by: 

  • ​Novo Nordisk Foundation
  • Danish Council for Independent Research; Medical Sciences 
  • Børnecacerfonden
  • Barncancerfonden (SE)
  • Svend Andersen Fonden
  • Aase og Ejnar Danielsens Fond
  • Danish Council for Strategic Research​

Selected publications​​

Theilgaard-Mönch K, Knudsen S, Follin P, Borregaard N. The transcriptional activation program of human neutrophils in skin lesions supports their important role in wound healing. J Immunol. 2004; 172:7684-93.

Theilgaard-Mönch K, Jacobsen LC, Borup R, Rasmussen T, Bjerregaard MD, Nielsen FC, Cowland JB, Borregaard. The Transcriptional Program of Terminal Granulocytic Differentiation. Blood. 2005; 105:1785-1796.

Theilgaard-Mönch K, Porse BT, Borregaard N. Systems biology of neutrophil differentiation and immune response. Curr Opin Immunol. 2006; 18:54-60.

Theilgaard-Mönch K, Jacobsen LC, Nielsen MJ, Rasmussen T, Udby L, Gharib M, Arkwright PD, Gombart AF, Calafat J, Moestrup SK, Porse BT, Borregaard N. Haptoglobin is synthesized during granulocyte differentiation, stored in specific granules, and released by neutrophils in response to activation. Blood. 2006;108:353-61.

Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C, Theilgaard-Mönch K, Minucci S, Porse BT, Marine J-C, Hansen KH, Helin K. The polycomb group proteins bind throughout the INK4AARF locus and are disassociated in senescent cells. Genes Dev. 2007;21:525-30.

Nilsson L, Edén P, Olsson E, Månsson R, Astrand-Grundström I, Strömbeck B, Theilgaard-Mönch K, Anderson K, Hast R, Hellström-Lindberg E, Samuelsson J, Bergh G, Nerlov C, Johansson B, Sigvardsson M, Borg A, Jacobsen SE. The molecular signature of MDS stem cells supports a stem-cell origin of 5q myelodysplastic syndromes. Blood. 2007;110:3005-14.

Borregaard N, Sørensen OE, Theilgaard-Mönch K. Neutrophil granules: a library of innate immunity proteins Trends Immunol. 2007; 28:340-5.

Hasemann MS, Damgaard I, Schuster MB, Theilgaard-Mönch K, Sorensen AB, Mrsic A, Krugers T, Ylstra B, Pedersen FS, Nerlov C, Porse BT. Mutation of C/EBPα predisposes to the development of myeloid leukemia in a retroviral insertional mutagenesis screen. Blood. 2008;111:4309-21. 

Kirstetter P, Schuster MB, Bereshchenko O, Moore S, Dvinge H, Kurz E, Moore S, Theilgaard-Mönch K, Månsson R,  Pedersen TÅ, Pabst T, Schröck E, Porse BT, Jacobsen SEW, Bertone P, Tenen DG, and Nerlov C. Modeling of C/EBPα mutant acute myeloid leukemia reveals a common  expression signature of committed myeloid leukemia initiating cells. Cancer Cell. 2008; 13:299-310. 

Marstrand TT, Borup R,  Willer A, Borregaard N, Sandelin A,  Porse BT, Theilgaard-Mönch K. A conceptual framework for the identification of candidate drugs and drug targets in acute promyelocytic leukemia. Leukemia. 2010 Jul;24(7):1265-75.

Theilgaard-Mönch K, Boultwood J, Ferrari S, Giannopoulos K, Hernandez-Rivas JM, Kohlmann A, Morgan M, Porse BT, Tagliafico E, Zwaan CM, Wainscoat J, Van den Heuvel-Eibrink MM, Ken Mills K, Bullinger L. Gene expression profiling in MDS and AML: Potential and future perspective. (review) Leukemia. 2011 Jun; 25(6):909-20.

Mora Jensen H, Jendholm J, Fossum A, Porse BT, Borregaad N, Theilgaard-Mönch K. Immunophenotypical characterization of human neutrophil differentiation. J Leukoc Biol. 2011.

Bagger FO, Rapin N, Theilgaard-Mönch K, Kaczkowski B, Jendholm J, Winther O, Porse B. HemaExplorer: a Web server for easy and fast visualization of gene expression in normal and malignant hematopoiesis. Blood. 2012 Jun 28;119(26):6394-5.

Rapin N, Bagger FO, Jendholm J, Mora-Jensen H, Krogh A, Kohlmann A, Thiede C, Borregaard N, Bullinger L, Winther O, Theilgaard-Mönch K and Porse BT (shared last authorship). Comparing cancer vs. normal gene expression profiles identifies new disease entities and common transcriptional programs in AML patients. Blood. 2014 Feb 6;123(6):894-904.

Mora-Jensen H, Jendholm J, Rapin N, Andersen MK, Roug AS, Bagger FO, Bullinger L, Winther O, Borregaard N, Porse BT, and Theilgaard-Mönch K. Cellular origin of prognostic chromosomal aberrations in AML patients. Leukemia, 2015, accepted for publication

​​​
Responsible editor